PMCB Earnings & Financial Statements
PharmaCyte Biotech, Inc.
$0.35
-$0.01(-2.08%)
28
Overall
60
Value
10
Tech
15
Quality
Market Cap
$3.74M
Volume
40.43K
52W Range
$0.33 - $1.51
Target Price
--
PMCB earnings and financial statements: PharmaCyte Biotech, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
PMCB Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating income | -$6.85M | -$4.38M | -$8.52M | -$6.46M | -$4.39M |
| EBITDA | -$19.42M | $30.66M | $333.8K | -$5.22M | -$4.24M |
| Net income | -$19.42M | $30.66M | $333.8K | -$4.32M | -$4.24M |
| EPS (diluted) | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $46.75M | $55.17M | $59.90M | $73.28M | $90.62M |
| Total liabilities | $11.77M | $3.28M | $20.39M | $586.6K | $704.4K |
| Shareholders’ equity | $33.29M | $51.89M | $27.65M | $72.69M | $89.92M |
| Cash and equivalents | $18.60M | $15.17M | $50.18M | $68.04M | $85.40M |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$5.15M | -$2.98M | -$2.15M | -$3.79M | -$4.12M |
| Free cash flow | -$5.15M | -$2.98M | -$2.15M | -$3.79M | -$4.12M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PMCB | $0.35 | -2.1% | 40.43K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get PharmaCyte Biotech, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW